The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Search Results for: sembiosys

Monday Biotech Deal Review: October 17, 2011

Welcome to your Monday Biotech Deal Review for October 17, 2011.  This week’s deal review is a double feature following last Monday’s Canadian thanksgiving holiday.  Of note from the past two weeks were the acquisition of Labopharm by Paladin Labs, and its announcement that it is ceasing its hostile takeover pursuit of Afexa. 

Monday Biotech Deal Review: March 21, 2011

Welcome to your Monday Biotech Deal Review for March 21, 2011.  There was some interesting investment and commercial transactions announced and closed last week, including the $15M private placement announced by Novadaq, the $4M bond financing closed by SemBioSys and Pacgen’s announcement of a corporate makeover to accommodate its recent investments in the products of […]

Monday Biotech Deal Review: February 21, 2011

Welcome to your Monday Biotech Deal Review for February 21, 2011.  Among other news, Angiotech made some progress this week in CCAA proceedings with respect to its recapitalization, and Merck Canada has made another investment in Quebec’s biopharma sector, investing $6.8M.  Read on to learn more.  

Monday Biotech Deal Review: February 14, 2011

Welcome to the Monday Biotech Deal Review for February 14, 2011.  Aside from the usual assortment of corporate and regulatory announcements over the week, the highlights include SemBioSys’ proposed $4M secured 7% bond issuance, Angiotech’s fifth extension to deadlines under its recapitalization support agreements (and definitive agreements in respect of up to $28M in DIP […]

Monday Biotech Deal Review: November 29, 2010

 Welcome to your Monday Biotech Deal Review.  I hope our American readers had a very happy thanksgiving weekend, but hopefully there’s still some room left for your weekly digest of biotech deals.  This week witnessed the closing of the US$52M IMRIS financing [Ed. -- as well as a rafter of other deals].  Read on to learn more about these and […]

Monday Biotech Deal Review: November 22, 2010

Welcome to your Monday Deal Review.  There was quite a bit of Canada / U.S. crossborder investment activity last week, with a $700M note offering by Valeant, IMRIS’ USD$52M public offering, and both IMRIS and Tekmira announcing their listing on the NASDAQ.   Read on to learn more, as well as the usual summaries of recent […]

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger. 

Monday Biotech Deal Review: September 27, 2010

Welcome to your Monday Biotech Deal Review. I am very excited to be writing for The Cross-Border Biotech Blog after working with Jeremy behind the scenes over the past three years. [ed. welcome (back) aboard!] It was a busy week for Canadian biotech companies, so let’s get started.

This Week in the Twitterverse: Weekend Reading

This week was full of news and analysis from the federal budget, so check that out by clicking here. When you’re done with that, here are some other good tidbits to catch up on over the weekend in case you missed them the first time around on @crossborderbio: RT @FDAcdrhIndustry: Deadline for commenting on 510(k) […]

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve […]

This Week in the Twitterverse: Weekend Reading

Here are some good tidbits to catch up on over the weekend in case you missed them the first time around on @crossborderbio: RT @ogilvyrenault: Convery and Chung contribute to @MaRSDD white paper on legal innovations in social entrepreneurship http://bit.ly/amRrY4  Oncothyreon $ONTY signs $8.4m SIFT/SR&ED arrangement http://bit.ly/981bBO like SemBioSys, ConjuChem, Vasogen http://bit.ly/cBL2qV  Labopharm closes $20m […]

Monday Biotech Deal Review: January 25, 2010

Everyone’s looking to the future in this week’s deal review: two special committees, 225,000 options, two royalty streams, a delisting notice and the first income trust/tax loss deal of 2010. 

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis […]

Monday Biotech Deal Review: December 14, 2009

In this week’s biotech deal review, some stimulus money finds its way to biotech, some M&A finds its way to shareholders’ votes, the NRC-BRI finds its way to two deals, and Patheon finds itself entering a new fiscal year a bit less burdened.  Even some securities may find their way into the market…

Monday Biotech Deal Review: November 23, 2009

A slightly delayed Deal Review this week because of some non-biotech deal activity.  Live, from New York, it’s the Deal Review!

Monday Biotech Deal Review: November 2, 2009

In this week’s Deal Review: SemBioSys hops on the SIFT Tax bandwagon; new deals from Microbix, OPMEDIC and GeneNews; and good updates from iCo Therapeutics, QLT, Noveko and Oncolytics.

Monday Biotech Deal Review: October 25, 2009

A very busy deal week coincided with a very busy work week (for those of us with day jobs), so allow me a particularly grateful thank-you to Jacob Cawker, who’s been an invaluable help with the Deal Review this and the last several weeks.  After the jump, licenses both inbound, outbound and just tied up (optioned); securities extended and […]

Monday Deal Review: August 3, 2009

Hopefully, the Deal Review will be a longer list as the newly-launched Ontario Emerging Technologies Fund starts deploying some capital, but for this week, the Canadian deal front was pretty quiet.   A few developments, like the JLL-Patheon pathos and the milestone for Cardiome from Merck, were noted at the time in our Twitter stream @crossborderbio, and […]

Monday Deal Review: July 27, 2009

Well, July is wrapping up with no sign of summer, or of the summer doldrums.  Read on for all the rainy-day deals we found this week

Monday Deal Review: June 22, 2009

A whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review.  Plus, a deal that may improve the medical isotope shortage.  

Monday Deal Review: May 11, 2009

Check out the latest Patheon-JLL developments, a licensing deal that looks like a subcontracting arrangement, a plan of arrangement M&A that looks like a license, and the rest of the Canadian deal info from this past week

Monday Deal Review: April 6, 2009

One complex arrangement, two clinical trial updates, three commercial deals and other bits of Canadian deal and company miscellany

Friday Science Review: March 20, 2009

I had a hard time finding news-making Canadian science stories this week; but in the meantime, here’s a  “numbers” edition of the Friday Science Review: Number of Canadians with cancer: Statistics Canada released its latest figures, showing that of all persons living in Canada on January 1, 2005, 695,000 had been diagnosed with an invasive cancer at some point […]

Follow

Get every new post delivered to your Inbox.

Join 130 other followers